Zi-Jun Zhang

Zi-Jun Zhang

Auto-generated profile, based on publicly available information

Zi-Jun Zhang

Hebei Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2025 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
QWQing-Bo Wang
Qing-Bo Wang
JLJin Li
Jin Li
ZZZi-Jun Zhang
Zi-Jun Zhang
YLYu-Kai Li
Yu-Kai Li
YLYu-Bo Liang
Yu-Bo Liang
YKYang Ke
Yang Ke
This review evaluates the efficacy and safety of therapies for hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT), inferior vena cava tumor thrombus (IVCTT), and/or right atrium tumor thrombus (RATT). A systematic review of PubMed, EMBASE, Cochrane Library, and Wanfang databases was conducted for literatures in this topic up to 22 August 2024, focusing on overall survival (OS), progression -free survival (PFS), and adverse reactions. Seven studies involving 453 patients were analyzed. The therapeutic strategies included surgery alone, local ± systemic therapy, and surgery with adjuvant therapy. The pooled 1-, 3-, and 5-year OS rates for all patients were 63.3% (95% CI 52.7%-73.9%), 21.6% (95% CI 4.9%-38.2%), and 8.3% (95% CI 2.9%-13.8%), respectively. Surgery with adjuvant therapy achieved the highest 1-year OS, while local ± systemic therapy led to the best 5-year OS. The pooled 1-, 3-, and 5-year PFS rates for all patients were 56.8% (95% CI 45.2%-68.4%), 9.4% (95% CI 0.0%-20.0%), and 1.6% (95% CI 0.0%-3.8%), respectively. Surgery alone frequently had adverse reactions of ascites and pleural effusion, the local ± systemic therapy frequently resulted in hepatic dysfunction and platelet abnormalities, and surgery and adjuvant therapy was frequently accompanied by peritoneal abscess. Local ± systemic therapy provided the best long-term OS and manageable complications among these three therapeutic strategies for HCC with HVTT, IVCTT, and/or RATT. PROSPERO, (CRD42024573152).